 Connection
Jennifer Kiser to Hepatitis C, Chronic
This is a "connection" page, showing publications Jennifer Kiser has written about Hepatitis C, Chronic.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
3.908 |
|
|
|
-
Kiser JJ. Safety of Hepatitis C Viral Protease Inhibitors in Compensated Cirrhotics: Lingering Concerns Put to Rest? Clin Infect Dis. 2019 10 30; 69(10):1665-1666.
Score: 0.579
-
Langness JA, Nguyen M, Wieland A, Everson GT, Kiser JJ. Optimizing hepatitis C virus treatment through pharmacist interventions: Identification and management of drug-drug interactions. World J Gastroenterol. 2017 Mar 07; 23(9):1618-1626.
Score: 0.482
-
Jimmerson LC, Clayton CW, MaWhinney S, Meissner EG, Sims Z, Kottilil S, Kiser JJ. Effects of ribavirin/sofosbuvir treatment and ITPA phenotype on endogenous purines. Antiviral Res. 2017 02; 138:79-85.
Score: 0.474
-
Kiser JJ. Clinically Significant Drug-Drug Interactions Between Hepatitis C Virus and HIV Treatments. Top Antivir Med. 2016 Oct/Nov; 24(3):106-110.
Score: 0.468
-
Wu LS, Rower JE, Burton JR, Anderson PL, Hammond KP, Baouchi-Mokrane F, Everson GT, Urban TJ, D'Argenio DZ, Kiser JJ. Population pharmacokinetic modeling of plasma and intracellular ribavirin concentrations in patients with chronic hepatitis C virus infection. Antimicrob Agents Chemother. 2015 Apr; 59(4):2179-88.
Score: 0.417
-
Kiser JJ, Burton JR, Everson GT. Drug-drug interactions during antiviral therapy for chronic hepatitis C. Nat Rev Gastroenterol Hepatol. 2013 Oct; 10(10):596-606.
Score: 0.374
-
Kiser JJ, Burton JR, Anderson PL, Everson GT. Review and management of drug interactions with boceprevir and telaprevir. Hepatology. 2012 May; 55(5):1620-8.
Score: 0.344
-
Steinbrink JM, Narayanasamy S, Wolfe CR, Maziarz E, Byrns J, Kiser JJ, Naggie S. Antiviral Treatment Failures After Transplantation of Organs From Donors With Hepatitis C Infection: A Report of 4 Cases. Am J Kidney Dis. 2023 09; 82(3):368-372.
Score: 0.182
-
Brooks KM, Castillo-Mancilla JR, Blum J, Huntley R, MaWhinney S, Alexander K, Kerr BJ, Ellison L, Bushman LR, MacBrayne CE, Anderson PL, Kiser JJ. Increased tenofovir monoester concentrations in patients receiving tenofovir disoproxil fumarate with ledipasvir/sofosbuvir. J Antimicrob Chemother. 2019 08 01; 74(8):2360-2364.
Score: 0.142
-
Jimmerson LC, Urban TJ, Truesdale A, Baouchi-Mokrane F, Kottilil S, Meissner EG, Sims Z, Langness JA, Hodara A, Aquilante CL, Kiser JJ. Variant Inosine Triphosphatase Phenotypes Are Associated With Increased Ribavirin Triphosphate Levels. J Clin Pharmacol. 2017 01; 57(1):118-124.
Score: 0.116
-
Fuchs EJ, Kiser JJ, Hendrix CW, Sulkowski M, Radebaugh C, Bushman L, Ray ML, Andrade A. Plasma and intracellular ribavirin concentrations are not significantly altered by abacavir in hepatitis C virus-infected patients. J Antimicrob Chemother. 2016 06; 71(6):1597-600.
Score: 0.112
-
Wu LS, Jimmerson LC, MacBrayne CE, Kiser JJ, D'Argenio DZ. Modeling Ribavirin-Induced Anemia in Patients with Chronic Hepatitis C Virus. CPT Pharmacometrics Syst Pharmacol. 2016 Feb; 5(2):65-73.
Score: 0.112
-
Rower JE, Meissner EG, Jimmerson LC, Osinusi A, Sims Z, Petersen T, Bushman LR, Wolfe P, McHutchison JG, Kottilil S, Kiser JJ. Serum and cellular ribavirin pharmacokinetic and concentration-effect analysis in HCV patients receiving sofosbuvir plus ribavirin. J Antimicrob Chemother. 2015 Aug; 70(8):2322-9.
Score: 0.106
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|